These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19962528)

  • 1. Editorial comment.
    Witjes JA
    Urology; 2009 Dec; 74(6):1281. PubMed ID: 19962528
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment.
    Herr HW
    Urology; 2009 Dec; 74(6):1280-1; author reply 1281. PubMed ID: 19962527
    [No Abstract]   [Full Text] [Related]  

  • 3. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer.
    Guzzo TJ; Magheli A; Bivalacqua TJ; Nielsen ME; Attenello FJ; Schoenberg MP; Gonzalgo ML
    Urology; 2009 Dec; 74(6):1276-80. PubMed ID: 19758684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of bladder tumors].
    Njinou B; Dardenne B; Darimont M; Wese FX; Van Cangh PJ
    Acta Urol Belg; 1999; 67(1):6-10. PubMed ID: 10859816
    [No Abstract]   [Full Text] [Related]  

  • 6. [International Consensus Panel--treatment strategies for superficial bladder cancer].
    Adler S; St Niclas M
    Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment.
    Kamat AM
    J Urol; 2009 Nov; 182(5):2203. PubMed ID: 19758663
    [No Abstract]   [Full Text] [Related]  

  • 8. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of BCG failures in superficial bladder cancer: a review.
    Witjes JA
    Eur Urol; 2006 May; 49(5):790-7. PubMed ID: 16464532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
    Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
    BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of BCG "Failures".
    Palou Redorta J
    Eur Urol; 2006 May; 49(5):779-80. PubMed ID: 16616207
    [No Abstract]   [Full Text] [Related]  

  • 12. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical cystectomy for BCG failure: has the timing improved in recent years?
    Brausi M
    BJU Int; 2011 Jul; 108(2):186. PubMed ID: 21718431
    [No Abstract]   [Full Text] [Related]  

  • 14. Is maintenance Bacillus Calmette-Guérin really necessary?
    Herr HW
    Eur Urol; 2008 Nov; 54(5):971-3. PubMed ID: 18585842
    [No Abstract]   [Full Text] [Related]  

  • 15. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?
    Herr HW; Sogani PC
    J Urol; 2001 Oct; 166(4):1296-9. PubMed ID: 11547061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T1G3 bladder tumours: the case for conservative treatment.
    Turner W
    Eur Urol; 2004 Apr; 45(4):401-5. PubMed ID: 15041101
    [No Abstract]   [Full Text] [Related]  

  • 18. [ BCG-immunotherapy and bladder cancer].
    Rischmann P
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Palou J; Rodríguez O; Segarra J; Rosales A
    J Urol; 2006 Jul; 176(1):407; author reply 407-8. PubMed ID: 16753451
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of high-risk, non-muscle-invasive bladder cancer.
    Lerner SP
    Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.